EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Sustained metabolic reduction and hypothermia in humans

Katharyn L Flickinger iD, Alexandra J Weissman iD, Francis X Guyette iD, Ryann DeMaio, Andrea Jonsson, Victor Wu, Jenna L Monteleone, Emma A Zurowski, Jonathan Birabaharan, Daniel J Buysse, Philip E Empey iD, Thomas D Nolin und 2 weitere

PLOS One · 2025

DOI: 10.1371/journal.pone.0321117 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Katharyn L Flickinger und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America. Hauptthemen laut MEDLINE: Dexmedetomidine, Hypothermia, Energy Metabolism. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NCATS NIH HHS, National Aeronautics and Space Administration.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic reduction is an adaptation employed by animals encountering environmental stressors or scarce resources. Lowering metabolism in humans may be useful to reduce consumables, oxygen utilization and carbon dioxide excretion. This is relevant for payload optimization or resource-restricted scenarios such as long-duration spaceflight or austere terrestrial environments (e.g., Arctic/Antarctic, submarine, cave or mine extraction). We previously demonstrated intravenous and single oral or sublingual doses of dexmedetomidine reduce oxygen consumption, wakefulness, and core body temperature in healthy humans. However, longer-acting dosing strategies are required to achieve greater levels of metabolic reduction. We explored whether a sublingual loading dose followed by subcutaneous infusion (SQI) of dexmedetomidine with and without surface cooling can decrease metabolic rate for 6 hours. We recruited 11 healthy volunteers, 4 male, median age 23 (IQR 21–25), who completed one-day laboratory studies measuring core body temperature via telemetry and metabolic rate via indirect calorimetry. Participants consumed an oral loading bolus of dexmedetomidine (2 μg/kg) followed by a six-hour SQI of dexmedetomidine (1 μg/kg/hr). Surface cooling pads were placed on the backs of 7 participants to promote heat loss. We collected vital signs continuously and monitored participants until they could be safely discharged. Energy expenditure (EE; kcals per day) dropped from baseline regardless of surface cooling. With surface cooling, median temperature decreased from 36.9°C (IQR 36.7–37.0°C) at baseline to 35.4°C (IQR 35.3–35.5°C) at 6 hours. Sublingual loading dose followed by 6-hour SQI of dexmedetomidine safely and effectively reduces metabolic rate. Future studies should be evaluating the effectiveness of SQI dexmedetomidine without a sublingual loading bolus, evaluating novel administration methods, and determining if tolerance develops with long-term use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DexmedetomidineHypothermiaEnergy MetabolismHumansMaleAdultFemaleYoung AdultBody TemperatureOxygen ConsumptionBasal MetabolismHealthy Volunteers

Substanzen

Dexmedetomidine

Autor:innen und Institutionen

  • Department of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.
  • University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania, United States of America.
  • Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.

ORCID-Profile: Katharyn L Flickinger, Alexandra J Weissman, Francis X Guyette, Philip E Empey

Förderung

  • NIH HHS
  • NCATS NIH HHS
  • National Aeronautics and Space Administration
  • NIH

Zitieren

APA

Flickinger, K. L., Weissman, A. J., Guyette, F. X., DeMaio, R., Jonsson, A., Wu, V., Monteleone, J. L., Zurowski, E. A., Birabaharan, J., Buysse, D. J., Empey, P. E., Nolin, T. D., West Iii, R. E., & Callaway, C. W. (2025). Sustained metabolic reduction and hypothermia in humans. PLOS One. https://doi.org/10.1371/journal.pone.0321117

Vancouver

Flickinger KL, Weissman AJ, Guyette FX, DeMaio R, Jonsson A, Wu V, et al. Sustained metabolic reduction and hypothermia in humans. PLOS One. 2025. doi:10.1371/journal.pone.0321117

BibTeX
@article{Flickinger2025,
  author = {Flickinger, Katharyn L and Weissman, Alexandra J and Guyette, Francis X and DeMaio, Ryann and Jonsson, Andrea and Wu, Victor and Monteleone, Jenna L and Zurowski, Emma A and Birabaharan, Jonathan and Buysse, Daniel J and Empey, Philip E and Nolin, Thomas D and West Iii, Raymond E and Callaway, Clifton W},
  title = {Sustained metabolic reduction and hypothermia in humans},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0321117}
}
Kostenlos starten →